Transfer and Survival of ST-Elevation Myocardial Infarction Medicare Patients

<i>Circulation: Cardiovascular Interventions</i> Editors’ Picks

Background: Morphine is commonly used for analgesia in the setting of chest discomfort associated with acute coronary syndromes (ACS). However, a retrospective analysis in non-ST elevation acute coronary syndrome (NSTE-ACS) patients suggesting increased mortality with morphine administration and further studies suggesting morphine may delay and inhibit the absorption of the oral anti-platelet agents has placed its utility in ACS under closer scrutiny. In a large single center retrospective study, we analyzed the association between morphine and in-hospital outcomes in ST elevation myocardial infarction (STEMI) and NST-ACS patients undergoing coronary angiogram +/- percutaneous coronary intervention (PCI). Methods: All STEMI and NSTE-ACS patients undergoing PCI between January 2009 and July 2016 in Massachusetts General Hospital were included in our study. Following institutional board review approval, baseline patient characteristics (demographics, risk factors and medical history) was obtained. In-hospital outcomes included mortality, post-procedure cardiogenic shock, length of hospital stay and infarct size as measured by troponin level. Results: Overall, 3027 patients were examined. Of those, 1287/3027 (42.52%) had STEMI, of which 359/1287 patients received morphine (27.89%). STEMI patients who received morphine were younger, had a higher prevalence of prior MI, PCI, and angina, were more likely to be on oxygen therapy, and had a longer time to PCI. 1740/3027 (57.48%) of study patients had NST-ACS, of which 424 (24.37%) received morphine. NSTE-ACS patients who received morphine were younger, had a higher prevalence of cerebrovascular disease, peripheral vascular disease, prior PCI, MI, congestive heart failure and valvular surgery. In unadjusted outcomes, STEMI patients who received morphine had a lower in-hospital mortality [4.18% versus 7.54%, odds ratio (OR): 0.53, p=0.03] and smaller infarct size (mean troponin level 0.75 ng/ml versus 1.29 ng/ml, p=0.02). There was no significant difference in post procedure cardiogenic shock or length of hospital stay (p= 0.26 and p=0.29 respectively). After adjusting for basic characteristics no outcomes remained significant in the STEMI cohort. In the NST-ACS cohort, patients who received morphine had a longer hospital stay (mean 6.58 days versus 4.78 days, p&lt;0.0001) and larger infarct size (mean troponin 1.16 ng/ml versus 0.90 ng/ml, p= 0.05). There was no statistical difference in in-hospital mortality or cardiogenic shock (p=0.17 and p=0.80 respectively). After adjusting for basic characteristics, length of hospital stay (p &lt;0.0001) and infarct size (p=0.02) remained significant. Conclusion: In a large retrospective study, morphine was associated with larger infarct size and a longer hospital admission in NSTE-ACS patients but had no effect on outcomes in STEMI patients.

P5476Usefulness of haemoglobin level combined with CAMI-STEMI score for predicting MACCE in patients with acute ST-elevation myocardial infarction after PCI

Creating an ideal system of care to address the care forpatients with ST-elevation myocardial infarction (STEMI) iscomplex from both the system’s and patient/family’s perspec-tives. In general, this care is unlike most other hospital care.It typically involves very fast and complex decision makingand, often, sudden transportation to another facility forpercutaneous coronary intervention (PCI). All of this occurswith a potentially critically ill patient and at a time when thefamily is often not immediately available. In this report, weaddress key perspectives from the patient and public point ofview of the current system of care for STEMI patients andhighlight the barriers and gaps that must be addressed by anideal system of care (Table 1).

A Multidisciplinary Approach to Reducing Door-to-Balloon Time in a Community Hospital

P5482The lipid paradox in patients with non-ST elevation and ST elevation myocardial infarction and percutaneous coronary intervention

A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients.

On- vs off-hours primary percutaneous coronary intervention: a single-centre experience

Funding Acknowledgements Type of funding sources: None. Background Multivessel disease is common (50%) in patients presenting with ST-segment elevation myocardial infarction (STEMI), and this is associated with a higher mortality compared to single-vessel disease. The optimal timing for revascularisation of significant non-infarct related artery (IRA) (non-culprit) lesions in STEMI patients remains controversial. The two main approaches include immediate revascularisation during the primary percutaneous coronary intervention (PPCI) or deferred (48 hours after the index procedure) percutaneous coronary intervention (PCI). The European Society of Cardiology guidelines recommend consideration of immediate non-IRA PCI in STEMI patients with cardiogenic shock, while revascularisation of other patients with non-IRA significant lesions should be considered prior to hospital discharge. Purpose To determine the optimal timing of intervention of significant non-IRA lesions in patients presenting with STEMI. Methods Coronary angiograms of nationwide STEMI patients who underwent a PPCI between 2013 and 2017 were reviewed to determine whether a significant non-IRA lesion was present (defined as &amp;gt;70% stenosis, or &amp;gt;50% of left main stem). The patients were divided into Group 1: immediate PCI of the non-IRA lesion during the PPCI, and Group 2: deferred PCI of non-IRA lesion prior to hospital discharge. Patients were followed up till end 2020 to determine whether a major adverse cardiovascular event occurred (death, myocardial infarction [MI], hospitalization due to pulmonary oedema and revascularization with repeat PCI and coronary artery bypass [CABG]). Chi-square and Fisher’s exact test were used for statistical analysis. Results 1080 patients underwent a PPCI between 2013 and 2017. 578 patients were excluded as they had no bystander disease, and a further 340 were excluded as they underwent CABG or medical treatment for the non-IRA lesions. From the remaining cohort, 55 patients were stratified to group 1 and 107 patients in group 2. There were no significant differences in baseline characteristics (Picture 1). Picture 2 demonstrates the distribution of non-IRAs which required PCI. Patients who had immediate non-IRA lesion PCI had a significantly higher mortality (Group 1, 21.8% vs Group 2, 8.4%, p=0.016) and more admissions with pulmonary oedema (Group 1, 10.9% vs Group 2, 0.9%, p=0.006). Group 1 patients were found to have a higher occurrence of cardiac arrest during the PPCI (10.9% vs 0.9%, p=0.006) and cardiogenic shock (12.7% vs 3.7%, p=0.046). There were no differences with regards to angina (p=0.386), MI (p=0.426) or re-vascularisation with repeat PCI (p= 0.090) or CABG (p=0.114). Conclusion STEMI patients who underwent immediate PCI to non-IRA lesions had a poorer outcome with higher rates of mortality and pulmonary oedema admissions compared to the deferred PCI cohort. Large randomised controlled trials are required to determine the optimal timing for intervention of significant non-IRA lesions.

<i>Circulation</i> Editors’ Picks

<i>Circulation</i> Editors’ Picks

Background: The presence of coronary vulnerable plaque has been shown to increase the risk of myocardial damage after percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients. It is possible that coronary plaque vulnerability may be assessed by evaluating plaque characteristics in other vessels such as the carotid arteries. Contrast-enhanced ultrasound (CEUS) of carotid plaque has been shown to detect the plaque neovascularization of carotid plaques, which is a feature of vulnerable plaque. Thus, in this study we examined whether CEUS of the carotid artery may provide information for myocardial damage risks after PCI in STEMI patients. Methods and Results: CEUS of the carotid plaques using perfluorobutane microbubbles as an ultrasound contrast agent were performed in consecutive 95 STEMI patients treated with emergent PCI. Intraplaque neovascularization was identified on the basis of microbubbles within the carotid plaque and graded as: G0, not visible; G1, moderate; or G2, extensive microbubbles. Obtained coronary flow and myocardial damage after PCI were estimated by corrected TIMI frame count (cTFC), Myocardial Blush Grade (MBG), peak CK-MB and Troponin T. The presence of G2 in the carotid arteries was associated with higher levels of cTFC (G0, 34±19 frames; G1, 41±21 frames; 43±24 frames,ρ=0.005) , lower levels of MBG (G0, 2.3±0.7; G1, 1.7±0.9; G2, 1.5±0.9,ρ=0.013), and higher levels of carotid IMT, fast blood glucose, hemoglobin A1c, hsCRP, and troponin T (ρ=0.049, 0.042, 0.046, 0.048, 0.01, and 0.02). Conclusion: The presence of carotid plaque neovascularization was related with myocardial damage after PCI in STEMI patients. Measurement of CEUS of Carotid Plaque is useful for risk stratification of STEMI patients underwent emergent PCI.

To describe the impact of delayed call time for chest pain in the salvage of ST-segment elevation myocardial infarction (STEMI) patients and its associated independent risk factors, and to identify risk factors associated with cumulative morbidity and mortality in STEMI patients at 4 years after percutaneous coronary intervention (PCI). Retrospective analysis of 398 patients diagnosed with STEMI and treated with emergency PCI within 24 hours of symptom onset in Fuyang People's Hospital from April 2018 to April 2021. The enrolled patients were divided into ≤60 minutes group (193 cases), and > 60 minutes group (205 cases), according to the delayed call time of patients with chest pain. Analysis of basic clinical data, rescue time, and major cardiovascular adverse events in the 2 groups. Multifactorial logistic regression analysis of independent correlates of delayed chest pain calls and Cox proportional risk regression modeling of risk factors for cumulative morbidity and mortality at 4 years after surgery. Compared to the delayed call time ≤ 60 minutes group, the > 60 minutes group had a higher proportion of females, a history of diabetes, rural remote areas, and farmer occupation (P < .05). Binary logistic regression analysis shows the history of diabetes and female as independent risk factors for delayed call time >60 minutes for chest pain. In the delayed call time ≤60 minutes group, the time from symptom onset-to-balloon (S0-to-B) and from symptom onset-to-first medical contact (SO-to-FMC) were smaller than in the delayed call time >60 minutes group (P < .05). The sum of postinfarction angina and major cardiovascular adverse events was lower in the group with delayed call time ≤60 minutes than in the group with delayed call time >60 minutes (P < .05). The Kaplan-Meier survival curve and the survival curve without the occurrence of major adverse cardiovascular events were statistically significant in both groups (P < .05). Multifactorial Cox regression analysis showed that delayed call time for chest pain >60 minutes, left main + 3 branch lesions, and cardiac function Killip ≥ III were all risk factors for cumulative morbidity and mortality at 4 years after PCI in patients with STEMI. Delayed call time for chest pain >60 minutes, left main + 3 branch lesions, and cardiac function Killip ≥ III are all risk factors for cumulative morbidity and mortality in STEMI patients at 4 years after PCI. Reducing the delayed call time for chest pain can improve the long-term prognosis of patients.

AimsTo perform a pairwise meta-analysis of randomized controlled trials (RCTs) comparing multivessel percutaneous coronary intervention (PCI) and culprit vessel-only PCI in ST-elevation myocardial infarction (STEMI) patients without cardiogenic shock.MethodsWe searched MEDLINE, Cochrane Central Register of Controlled Trials, and Embase for RCTs comparing multivessel PCI with culprit vessel-only PCI in STEMI patients without cardiogenic shock and multivessel coronary artery disease. Only RCTs reporting mortality or myocardial reinfarction after at least 6 months following randomization were included. Hazard ratios (HRs) were pooled using random-effect models.ResultsNine RCTs were included in the final analysis. In total, 523 (8.3%) of 6314 patients suffered the combined primary endpoint of death or non-fatal reinfarction. This primary endpoint was significantly reduced with multivessel PCI compared to culprit vessel-only PCI (HR 0.63, 95% confidence interval [CI] 0.43–0.93; p = 0.03). This finding was driven by a reduction of non-fatal reinfarction (HR 0.64, 95% CI 0.52–0.79; p = 0.001), whereas no significant reduction of all-cause death (HR 0.77, 95% CI 0.44–1.35; p = 0.28) or cardiovascular death (HR 0.64, 95% CI 0.37–1.11; p = 0.09) was observed.ConclusionsIn STEMI patients without cardiogenic shock multivessel PCI reduced the risk of death or non-fatal reinfarction compared to culprit vessel-only PCI.

BackgroundNew-onset atrial fibrillation (NOAF) is associated with worse prognostic outcomes in cases diagnosed with ST-segment elevation myocardial infarction (STEMI) patients after percutaneous coronary intervention (PCI). The triglyceride-glucose (TyG) index, as a credible and convenient marker of insulin resistance, has been shown to be predictive of outcomes for STEMI patients following revascularization. The association between TyG index and NOAF among STEMI patients following PCI, however, has not been established to date.ObjectiveTo assess the utility of the TyG index as a predictor of NOAF incidence in STEMI patients following PCI, and to assess the relationship between NOAF and long-term all-cause mortality.MethodsThis retrospective cohort research enrolled 549 STEMI patients that had undergone PCI, with these patients being clustered into the NOAF group and sinus rhythm (SR) group. The predictive relevance of TyG index was evaluated through logistic regression analyses and the receiver operating characteristic (ROC) curve. Kaplan-Meier curve was employed to explore differences in the long-term all-cause mortality between the NOAF and SR group.ResultsNOAF occurred in 7.7% of the enrolled STEMI patients after PCI. After multivariate logistic regression analysis, the TyG index was found to be an independent predictor of NOAF [odds ratio (OR): 8.884, 95% confidence interval (CI): 1.570–50.265, P = 0.014], with ROC curve analyses further supporting the predictive value of this parameter, which exhibited an area under ROC curve of 0.758 (95% CI: 0.720–0.793, P < 0.001). All-cause mortality rates were greater for patients in the NOAF group in comparison with the SR group over a median 35-month follow-up period (log-rank P = 0.002).ConclusionsThe TyG index exhibits values as an independent predictor of NOAF during hospitalization, which indicated a poorer prognosis after a relatively long-term follow-up.